Zacks Research Issues Negative Forecast for FMS Earnings

Fresenius Medical Care AG (NYSE:FMS) – Equities researchers at Zacks Research lowered their Q4 2024 earnings estimates for shares of Fresenius Medical Care in a report issued on Monday, December 30th. Zacks Research analyst I. Bandyopadhyay now anticipates that the company will post earnings of $0.38 per share for the quarter, down from their previous forecast of $0.39. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.55 per share. Zacks Research also issued estimates for Fresenius Medical Care’s Q1 2025 earnings at $0.39 EPS, Q2 2025 earnings at $0.42 EPS, Q3 2025 earnings at $0.53 EPS, Q4 2025 earnings at $0.54 EPS, FY2025 earnings at $1.87 EPS, Q1 2026 earnings at $0.46 EPS, Q2 2026 earnings at $0.47 EPS, Q3 2026 earnings at $0.59 EPS and FY2026 earnings at $2.13 EPS.

A number of other analysts also recently issued reports on FMS. Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. Truist Financial boosted their price target on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective for the company. Finally, StockNews.com started coverage on shares of Fresenius Medical Care in a report on Thursday, November 28th. They issued a “strong-buy” rating on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Fresenius Medical Care currently has a consensus rating of “Hold” and an average price target of $24.30.

Fresenius Medical Care Trading Down 2.2 %

Shares of FMS stock opened at $22.15 on Wednesday. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $13.00 billion, a price-to-earnings ratio of 18.31, a price-to-earnings-growth ratio of 0.96 and a beta of 0.93. Fresenius Medical Care has a 12-month low of $17.93 and a 12-month high of $24.31. The stock’s 50-day moving average price is $22.21 and its 200-day moving average price is $20.64.

Hedge Funds Weigh In On Fresenius Medical Care

Large investors have recently modified their holdings of the stock. Wulff Hansen & CO. grew its stake in shares of Fresenius Medical Care by 1,809.0% during the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after buying an additional 325,439 shares during the last quarter. Moran Wealth Management LLC grew its position in Fresenius Medical Care by 47.0% in the 3rd quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock valued at $4,971,000 after acquiring an additional 74,621 shares during the last quarter. Quantinno Capital Management LP increased its stake in Fresenius Medical Care by 78.9% in the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after purchasing an additional 48,554 shares during the period. Triasima Portfolio Management inc. lifted its position in shares of Fresenius Medical Care by 27.4% during the second quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company’s stock worth $1,631,000 after purchasing an additional 18,360 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of Fresenius Medical Care by 3.3% during the third quarter. Franklin Resources Inc. now owns 74,640 shares of the company’s stock worth $1,490,000 after purchasing an additional 2,386 shares during the last quarter. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.